Neuroprotective Role for Galanin in Alzheimer’s Disease
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Galanin (GAL) and GAL receptors (GALR) are overexpressed in degenerating brain regions associated with cognitive decline in Alzheimer’s disease (AD). The functional consequences of GAL plasticity in AD are unclear. GAL inhibits cholinergic transmission in the hippocampus and impairs spatial memory in rodent models, suggesting that GAL overexpression exacerbates cognitive impairment in AD. By contrast, gene expression profiling of individual cholinergic basal forebrain (CBF) neurons aspirated from AD tissue revealed that GAL hyper-innervation positively regulates mRNAs that promote CBF neuronal function and survival. GAL also exerts neuroprotective effects in rodent models of neurotoxicity. These data support the growing concept that GAL overexpression preserves CBF neuron function, which may in turn delay the onset of symptoms of AD. Further elucidation of GAL activity in selectively vulnerable brain regions will help gauge the therapeutic potential of GALR ligands in the treatment of AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mesulam, M. ‐., Mufson, E. J., Levey, A. I., & Wainer, B. H. (1983) · Journal of Comparative Neurology · doi:10.1002/cne.902140206 · Cited by 1,962
Self-citationProfound Loss of Layer II Entorhinal Cortex Neurons Occurs in Very Mild Alzheimer’s Disease
Gómez-Isla, T., Price, J. L., McKeel Jr., D. W., Morris, J. C., Growdon, J. H., & Hyman, B. T. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-14-04491.1996 · Cited by 1,796 · cited 2×
“Hence, increased GALR binding occurs in select cognitive regions of the AD brain that are affected during the prodromal stages of AD [29, 31].”
BackgroundA phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease
Tuszynski, M. H., Thal, L., Pay, M., Salmon, D. P., U, H. S., Bakay, R., Patel, P., Blesch, A., Vahlsing, H. L., Ho, G., et al. (2005) · Nature Medicine · doi:10.1038/nm1239 · Cited by 1,050 · cited 1×
“In this regard, intraventricular infusion of NGF increased GAL mRNA expression in the hippocampus of rats [102] suggesting that the use of NGF in the treatment of AD [103] may indirectly increase GAL in the brain, thus providing a dual therapeutic benefit for treatment of CBF dysfunction in AD.”
BackgroundSelf-citationImpaired Proteasome Function in Alzheimer's Disease
Keller, J. N., Hanni, K. B., & Markesbery, W. R. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0750436.x · Cited by 848 · cited 1×
“Functionally, posttranslational modification of proteins by ubiquitination regulates a wide range of cellular actions including protein stability and transport [70–72].”
BackgroundBartus, R. T. (2000) · Experimental Neurology · doi:10.1006/exnr.2000.7397 · Cited by 829 · cited 1×
“role in memory and attention functions [8].”
Choi, J., Levey, A. I., Weintraub, S. T., Rees, H. D., Gearing, M., Chin, L.-S., & Li, L. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m314124200 · Cited by 568 · cited 1×
“Functionally, posttranslational modification of proteins by ubiquitination regulates a wide range of cellular actions including protein stability and transport [70–72].”
BackgroundWilcock, G. K., Esiri, M. M., Bowen, D. M., & Smith, C. C. T. (1982) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(82)90045-4 · Cited by 553
Niendorf, S., Oksche, A., Kisser, A., Löhler, J., Prinz, M., Schorle, H., Feller, S., Lewitzky, M., Horak, I., & Knobeloch, K.-P. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.01566-06 · Cited by 207
Holmes, A., Kinney, J. W., Wrenn, C. C., Li, Q., Yang, R. J., Ma, L., Vishwanath, J., Saavedra, M. C., Innerfield, C. E., Jacoby, A. S., et al. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300164 · Cited by 202 · cited 1×
“Likewise, studies of GALR1KO and GALR2KO mouse strains implicate both receptors in mediating anxiolytic actions [93, 94].”
Background
Cited by
Lang, R., Gundlach, A. L., Holmes, F. E., Hobson, S. A., Wynick, D., Hökfelt, T., & Kofler, B. (2015) · Pharmacological Reviews · doi:10.1124/pr.112.006536 · Cited by 327
Long Road to Ruin: Noradrenergic Dysfunction in Neurodegenerative Disease
Weinshenker, D. (2018) · Trends in Neurosciences · doi:10.1016/j.tins.2018.01.010 · Cited by 323
The genetics of familial combined hyperlipidaemia
Brouwers, M. C. G. J., van Greevenbroek, M. M. J., Stehouwer, C. D. A., de Graaf, J., & Stalenhoef, A. F. H. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.15 · Cited by 109
Developmental specification of forebrain cholinergic neurons
Allaway, K. C., & Machold, R. (2017) · Developmental Biology · doi:10.1016/j.ydbio.2016.11.007 · Cited by 68
Qiu, Y., Hou, Y., Gohel, D., Zhou, Y., Xu, J., Bykova, M., Yang, Y., Leverenz, J. B., Pieper, A. A., Nussinov, R., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114128 · Cited by 40
“59,60 GALR1 and FPR1 interact with linolenic acid and 5-phenylvaleric acid, respectively (Figure 4C).”
Metadata
- Authors
- Counts, S. E., Perez, S. E., Ginsberg, S. D., & Mufson, E. J.
- Venue
- Experientia Supplementum
- Publisher
- Springer Basel
- Published
- 2010
- Volume
- 102
- Pages
- 143-162
- ISSN
- 1023-294X (ISSN-L)
- OpenAlex
- W40297490
- Cited by
- 52
- References
- 9
- FWCI
- 10.78
- Type
- book chapter
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neuroprotective Role for Galanin in Alzheimer’s Disease. https://app.cochat.ai/papers/10.1007/978-3-0346-0228-0_11
- The paper
- Counts, S. E., Perez, S. E., Ginsberg, S. D., & Mufson, E. J. (2010). Neuroprotective Role for Galanin in Alzheimer’s Disease. Experientia Supplementum. https://doi.org/10.1007/978-3-0346-0228-0_11
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.